share_log

艾美疫苗：自願性公告 - b型流感嗜血桿菌結合疫苗提交臨床試驗預申請

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE SUBMIT

香港交易所 ·  Mar 27 20:03
Summary by Moomoo AI
艾美疫苗股份有限公司（「艾美疫苗」）近日對外宣佈，公司已於2024年3月27日提交b型流感嗜血桿菌結合疫苗的臨床試驗預申請，並於2024年2月9日提交吸附破傷風疫苗的臨床試驗預申請。這兩款疫苗的研發是公司實現研發多聯多價產品戰略的重要一環，旨在完善產品結構。艾美疫苗亦正在推進多聯疫苗的研發，該疫苗可預防多種疾病，預計從2024年開始提交臨床試驗申請，有助於減少嬰幼兒接種次數並提高接種依從性。該公司認為多聯疫苗的研發將有助於增強其市場地位及核心競爭力，為公司的持續穩健發展提供支持。艾美疫苗的董事會成員包括多位專業人士，由周延先生擔任董事會主席、執行董事兼首席執行官。
艾美疫苗股份有限公司（「艾美疫苗」）近日對外宣佈，公司已於2024年3月27日提交b型流感嗜血桿菌結合疫苗的臨床試驗預申請，並於2024年2月9日提交吸附破傷風疫苗的臨床試驗預申請。這兩款疫苗的研發是公司實現研發多聯多價產品戰略的重要一環，旨在完善產品結構。艾美疫苗亦正在推進多聯疫苗的研發，該疫苗可預防多種疾病，預計從2024年開始提交臨床試驗申請，有助於減少嬰幼兒接種次數並提高接種依從性。該公司認為多聯疫苗的研發將有助於增強其市場地位及核心競爭力，為公司的持續穩健發展提供支持。艾美疫苗的董事會成員包括多位專業人士，由周延先生擔任董事會主席、執行董事兼首席執行官。
Amy Vaccines Co., Ltd. (“Amy Vaccines”) has recently announced that it has submitted a pre-application for clinical trial of the combination vaccine against Haemophilus influenza b on March 27, 2024 and a pre-application for clinical trial of the aspirated pneumococcal influenza vaccine on February 9, 2024. The research and development of these two vaccines is an important part of the company's strategy to develop multi-valued products, aimed at perfecting the product structure. EME is also advancing the development of a multidine vaccine that can prevent a variety of diseases and is expected to apply for clinical trials starting in 2024, helping to reduce infant immunizations and increase vaccination adherence. The Company believes that the R&D of the multidone vaccine will help strengthen its market position and core competitiveness, supporting the company's continued and robust development. The Board of Directors of Amy Vaccines includes a number of professionals, with Mr. Zhou Yan serving as Chairman of the Board, Executive Director and Chief Executive Officer.
Amy Vaccines Co., Ltd. (“Amy Vaccines”) has recently announced that it has submitted a pre-application for clinical trial of the combination vaccine against Haemophilus influenza b on March 27, 2024 and a pre-application for clinical trial of the aspirated pneumococcal influenza vaccine on February 9, 2024. The research and development of these two vaccines is an important part of the company's strategy to develop multi-valued products, aimed at perfecting the product structure. EME is also advancing the development of a multidine vaccine that can prevent a variety of diseases and is expected to apply for clinical trials starting in 2024, helping to reduce infant immunizations and increase vaccination adherence. The Company believes that the R&D of the multidone vaccine will help strengthen its market position and core competitiveness, supporting the company's continued and robust development. The Board of Directors of Amy Vaccines includes a number of professionals, with Mr. Zhou Yan serving as Chairman of the Board, Executive Director and Chief Executive Officer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more